
Cambridge Cognition
Cognitive assessment software for clinical trials, academic research and healthcare.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | N/A | £2.6m | Post IPO Equity |
Total Funding | 000k |





GBP | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | 50 % | 25 % | 7 % | (23 %) | (8 %) | 28 % | 41 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | 4 % | - | (9 %) | (4 %) | (4 %) | 9 % | 24 % |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | 4 % | (3 %) | (26 %) | (17 %) | - | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
R&D % of revenue | - | 18 % | 28 % | 25 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Cambridge Cognition Holdings PLC operates as a neuroscience technology company, specializing in digital solutions for assessing brain health. The company's origins trace back to 1984 with the development of the Cambridge Neuropsychological Test Automated Battery (CANTAB) by Professors Trevor Robbins and Barbara Sahakian at the University of Cambridge. This foundational research aimed to bridge the gap between basic neuroscience and traditional neuropsychological testing. Robbins, a professor of cognitive neuroscience, and Sahakian, a professor of clinical neuropsychology, brought their extensive research in brain function, psychopharmacology, and cognitive dysfunction to the creation of CANTAB, establishing a lifelong professional and personal partnership. In 2002, Cambridge Cognition Ltd. was spun out of the university to commercialize this technology and went public on the AIM market of the London Stock Exchange in 2013.
The company's business model is centered on providing digital health products and services to the pharmaceutical and healthcare industries, primarily focusing on the clinical trials market. Revenue is generated by offering its proprietary software and services to pharmaceutical and biotech companies, academic institutions, and healthcare organizations to support clinical trials for central nervous system (CNS) disorders. Clients use the company's tools to assess the efficacy and safety of new drugs by measuring cognitive outcomes in patients. The company serves a global market, with a significant presence in the US, Europe, and an expanding reach in Asia through partnerships. Key clients include the world's leading pharmaceutical companies, with a significant portion of revenue coming from its top 10 long-term customers.
The core product, CANTAB, is a highly validated suite of touchscreen-based cognitive assessments. This platform features non-verbal, game-like tests that measure various aspects of cognitive function, including memory, attention, executive function, and learning. A key feature is its sensitivity in detecting subtle cognitive changes, which is crucial for early detection of conditions like Alzheimer's disease and for evaluating treatment effects in clinical trials. Over the years, the product line has expanded to include voice analysis technology (NeuroVocalix® and Winterlight), electronic questionnaires (eCOA), and high-frequency testing via wearables. The company also provides an end-to-end platform for managing decentralized and hybrid clinical trials, which became increasingly important following the shift to remote trial management. In 2023, the company launched AQUA, an automated quality assurance product derived from its acquisition of Winterlight Labs.
Keywords: cognitive assessment, brain health, clinical trials, digital neuroscience, CANTAB, neuropsychological testing, pharmaceutical services, CNS disorders, eCOA, decentralized clinical trials, voice biomarkers, cognitive testing software, neurotechnology, clinical trial solutions, Alzheimer's research, cognitive endpoints, digital biomarkers, neuropsychology, psychopharmacology, clinical data management, virtual clinical trials, remote patient monitoring
Tech stack
Investments by Cambridge Cognition
Edit
